ImmunoBiome

[Not Yet Scheduled]
Our company develops novel drug candidates targeting intractable immune diseases. Drug
candidates include Active Pharmaceutical Ingredients (API) and Live Biotherapeutic Products
(LBP) to enhance anti-cancer immunity or to suppress inflammatory immune responses, depending on the drug candidate.
Using an innovative Next Generation Immunotyping System of ImmunoBiome (Avatiome™), we have
further identified key effector molecules from LBP candidates and defined their mechanisms of action, enabling us to design the optimal combination drugs rationally.
Based on our solid scientific infrastructures (Germ-Free mouse facility), qualified scientist (Immunologist and AI specialist), and merits of academic research environment (located in POSTECH campus), we could accelerate the development process and publish papers in prestigious academic journals. Currently, we are developing two LBP candidates, IMB001 and IMB002, targeting cancer and inflammatory disorders.
Company Type:
Privately Funded Company
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
June 2019
Main Therapeutic Focus:
Lead Product in Development:
IMB001 for anti-cancer, IMB002 for autoimmune diseases
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
ImmunoBiome